HomeCompareAIQUY vs ABBV

AIQUY vs ABBV: Dividend Comparison 2026

AIQUY yields 1.75% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $68.3K in total portfolio value
10 years
AIQUY
AIQUY
● Live price
1.75%
Share price
$41.50
Annual div
$0.73
5Y div CAGR
29.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.0K
Annual income
$3,492.07
Full AIQUY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AIQUY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAIQUYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AIQUY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AIQUY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AIQUY
Annual income on $10K today (after 15% tax)
$148.84/yr
After 10yr DRIP, annual income (after tax)
$2,968.26/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $18,087.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AIQUY + ABBV for your $10,000?

AIQUY: 50%ABBV: 50%
100% ABBV50/50100% AIQUY
Portfolio after 10yr
$68.2K
Annual income
$14,131.92/yr
Blended yield
20.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AIQUY
Analyst Ratings
4
Buy
1
Sell
Consensus: Buy
Altman Z
4.8
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AIQUY buys
0
ABBV buys
0
No recent congressional trades found for AIQUY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAIQUYABBV
Forward yield1.75%3.06%
Annual dividend / share$0.73$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR29.1%40.6%
Portfolio after 10y$34.0K$102.3K
Annual income after 10y$3,492.07$24,771.77
Total dividends collected$12.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: AIQUY vs ABBV ($10,000, DRIP)

YearAIQUY PortfolioAIQUY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,926$226.06$11,550$430.00$624.00ABBV
2$11,989$298.01$13,472$627.96$1.5KABBV
3$13,223$394.53$15,906$926.08$2.7KABBV
4$14,673$525.01$19,071$1,382.55$4.4KABBV
5$16,403$702.94$23,302$2,095.81$6.9KABBV
6$18,500$948.12$29,150$3,237.93$10.7KABBV
7$21,085$1,290.15$37,536$5,121.41$16.5KABBV
8$24,335$1,774.14$50,079$8,338.38$25.7KABBV
9$28,509$2,470.53$69,753$14,065.80$41.2KABBV
10$33,997$3,492.07$102,337$24,771.77$68.3KABBV

AIQUY vs ABBV: Complete Analysis 2026

AIQUYStock

L'Air Liquide S.A. provides gases, technologies, and services for the industrial and health sectors in Europe, the Americas, the Asia Pacific, the Middle East, and Africa. The company's Gas & Services segment offers oxygen, nitrogen, argon, hydrogen, and carbon monoxide to the metals, chemicals, refining, and energy sectors; and gases, application equipment, and associated services to the materials and energy, automotive and manufacturing, food and pharmaceuticals, technology and research, and craftsmen and retail sectors. It also supplies medical gases, hygiene products, equipment, and services to hospitals, as well as to patients in their homes; and produces and distributes healthcare specialty ingredients for the cosmetics, pharmaceutical, and vaccine markets. In addition, this segment supplies gases, materials, and services for use in the production of semi-conductors, as well as flat screens and photovoltaic panels. Its Engineering & Construction segment designs, develops, and builds industrial gas production plants for third parties; and designs and manufactures plants in the traditional, renewable, and alternative energy sectors. The company's Global Markets & Technologies segment delivers technological solutions, such as molecules, equipment, and services to support the markets of energy transition, primarily in transport, energy, and waste valorization, as well as related to deep tech in the space exploration, aerospace, and big science. This segment also invests in biomethane production units, as well as develops stations for distributing natural bio-gas for vehicles and hydrogen to support clean mobility; operates biomethane production units for use in the maritime industry; and supplies gases for the offshore oil and gas platforms, offshore wind turbines, and cryogenic transportation by sea. L'Air Liquide S.A. was incorporated in 1902 and is headquartered in Paris, France.

Full AIQUY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AIQUY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AIQUY vs SCHDAIQUY vs JEPIAIQUY vs OAIQUY vs KOAIQUY vs MAINAIQUY vs JNJAIQUY vs MRKAIQUY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.